US5223499A
(en)
*
|
1989-05-30 |
1993-06-29 |
Merck & Co., Inc. |
6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
|
US5332744A
(en)
*
|
1989-05-30 |
1994-07-26 |
Merck & Co., Inc. |
Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
|
IE70593B1
(en)
*
|
1989-09-29 |
1996-12-11 |
Eisai Co Ltd |
Biphenylmethane derivative the use of it and pharmacological compositions containing same
|
US5196444A
(en)
*
|
1990-04-27 |
1993-03-23 |
Takeda Chemical Industries, Ltd. |
1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
|
DE4036706A1
(de)
*
|
1990-11-17 |
1992-05-21 |
Hoechst Ag |
Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
|
GB9027208D0
(en)
*
|
1990-12-14 |
1991-02-06 |
Smithkline Beecham Plc |
Medicaments
|
GB9027198D0
(en)
*
|
1990-12-14 |
1991-02-06 |
Smithkline Beecham Plc |
Medicaments
|
SI9210098B
(sl)
*
|
1991-02-06 |
2000-06-30 |
Dr. Karl Thomae |
Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
|
FR2673427B1
(fr)
*
|
1991-03-01 |
1993-06-18 |
Sanofi Elf |
Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
|
TW274551B
(sv)
*
|
1991-04-16 |
1996-04-21 |
Takeda Pharm Industry Co Ltd |
|
IL102183A
(en)
*
|
1991-06-27 |
1999-11-30 |
Takeda Chemical Industries Ltd |
The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
|
US5354759A
(en)
*
|
1991-09-12 |
1994-10-11 |
Fujisawa Pharmaceutical Co., Ltd. |
Angiotenin II antagonizing heterocyclic compounds
|
GB9201789D0
(en)
*
|
1992-01-28 |
1992-03-11 |
Fujisawa Pharmaceutical Co |
Heterocyclic derivatives
|
TW284688B
(sv)
*
|
1991-11-20 |
1996-09-01 |
Takeda Pharm Industry Co Ltd |
|
JP2682353B2
(ja)
*
|
1991-11-20 |
1997-11-26 |
武田薬品工業株式会社 |
経口用医薬組成物およびその製造法
|
DE4203872A1
(de)
*
|
1992-02-11 |
1993-08-12 |
Thomae Gmbh Dr K |
Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
|
JPH07507271A
(ja)
*
|
1992-03-03 |
1995-08-10 |
藤沢薬品工業株式会社 |
アンジオテンシン11拮抗剤としてのベンズイミダゾール誘導体
|
US5310929A
(en)
*
|
1992-08-06 |
1994-05-10 |
E. I. Du Pont De Nemours And Company |
Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
|
US5266583A
(en)
*
|
1992-09-01 |
1993-11-30 |
Merck & Co., Inc. |
Angitotensin II antagonist
|
DK154092D0
(da)
*
|
1992-12-23 |
1992-12-23 |
Neurosearch As |
Imidazolforbindelser, deres fremstilling og anvendelse
|
CA2115985A1
(en)
*
|
1993-02-25 |
1994-08-26 |
Kohei Nishikawa |
Vascular hypertrophy suppressor
|
JP2787539B2
(ja)
*
|
1993-02-26 |
1998-08-20 |
松森 昭 |
ウイルス性疾患の予防または治療剤
|
JP3810020B2
(ja)
*
|
1993-04-22 |
2006-08-16 |
武田薬品工業株式会社 |
腎疾患の予防または治療剤
|
JP2003306432A
(ja)
*
|
1993-04-22 |
2003-10-28 |
Takeda Chem Ind Ltd |
腎疾患の予防または治療剤
|
JP3057471B2
(ja)
*
|
1993-06-07 |
2000-06-26 |
武田薬品工業株式会社 |
アンジオテンシンii介在性諸疾患の予防または治療剤
|
US5721263A
(en)
|
1993-06-07 |
1998-02-24 |
Takeda Chemical Industries, Ltd. |
Pharmaceutical composition for angiotensin II-mediated diseases
|
CA2125251C
(en)
*
|
1993-06-07 |
2005-04-26 |
Yoshiyuki Inada |
A pharmaceutical composition for angiotensin ii-mediated diseases
|
CZ154994A3
(en)
*
|
1993-07-02 |
1995-09-13 |
Senju Pharma Co |
Visual hypotensive agent
|
US5391566A
(en)
*
|
1993-07-20 |
1995-02-21 |
Merck & Co., Inc. |
Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
|
ZA945190B
(en)
*
|
1993-07-30 |
1995-02-24 |
Kotobuki Seiyaku Co Ltd |
Carboxymethylidenecycloheptimidazole derivatives method or manufacturing the same and therapeutic agents containing these compounds
|
US5824696A
(en)
*
|
1993-09-01 |
1998-10-20 |
Smithkline Beecham Corporation |
Medicaments
|
US6676967B1
(en)
*
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
ATE194603T1
(de)
*
|
1994-01-28 |
2000-07-15 |
Takeda Chemical Industries Ltd |
Ein verfahren zur herstellung von tetrazolyl- verbindungen
|
DE4408497A1
(de)
*
|
1994-03-14 |
1995-09-21 |
Thomae Gmbh Dr K |
Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
HUT74734A
(en)
*
|
1994-03-16 |
1997-02-28 |
Sankyo Co |
Use of biphenyl methyl imidazole derivatives for producing pharmaceutical compositions having ocular tension derpessant activity
|
AU677702B2
(en)
*
|
1994-10-13 |
1997-05-01 |
Takeda Pharmaceutical Company Limited |
A prophylactic or therapeutic drug for renal diseases
|
SE9501881D0
(sv)
*
|
1995-05-19 |
1995-05-19 |
Astra Ab |
New pharmacological use of AII-receptor antagonists
|
SE9502219D0
(sv)
*
|
1995-06-19 |
1995-06-19 |
Astra Ab |
Novel medical use
|
CA2232663C
(en)
*
|
1995-10-06 |
2008-04-08 |
Novartis Ag |
At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
|
DK0882718T3
(da)
*
|
1995-12-28 |
2005-12-12 |
Astellas Pharma Inc |
Benzimidazolderivater
|
JP4369994B2
(ja)
|
1996-02-29 |
2009-11-25 |
ノバルティス アクチエンゲゼルシャフト |
アポトーシスの刺激のためのat▲下1▼レセプターアンタゴニスト
|
CN1215338A
(zh)
*
|
1996-04-05 |
1999-04-28 |
武田药品工业株式会社 |
包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物
|
US5771604A
(en)
*
|
1997-04-07 |
1998-06-30 |
Maytag Corporation |
Clothes dryer air inlet arrangement
|
US6177587B1
(en)
|
1997-05-26 |
2001-01-23 |
Takeda Chemical Industries, Ltd. |
Production method of aminobenzene compound
|
TW453999B
(en)
|
1997-06-27 |
2001-09-11 |
Fujisawa Pharmaceutical Co |
Benzimidazole derivatives
|
WO1999020260A2
(en)
|
1997-10-17 |
1999-04-29 |
Eurogene Limited |
The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
|
AU745838B2
(en)
|
1998-02-23 |
2002-04-11 |
Kureha Chemical Industry Co., Ltd. |
Benzimidazole derivative
|
DE19820151A1
(de)
*
|
1998-05-06 |
1999-11-11 |
Hexal Ag |
Transdermales therapeutisches System zur Anwendung von Candesartan
|
US6638937B2
(en)
|
1998-07-06 |
2003-10-28 |
Bristol-Myers Squibb Co. |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
JP3923255B2
(ja)
|
1998-07-15 |
2007-05-30 |
帝人株式会社 |
チオベンズイミダゾール誘導体
|
ATE354364T1
(de)
|
1998-12-23 |
2007-03-15 |
Novartis Pharma Gmbh |
Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind
|
US6465502B1
(en)
|
1998-12-23 |
2002-10-15 |
Novartis Ag |
Additional therapeutic use
|
CN101011390A
(zh)
|
1999-01-26 |
2007-08-08 |
诺瓦提斯公司 |
血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
|
GB0001662D0
(en)
*
|
1999-02-06 |
2000-03-15 |
Zeneca Ltd |
Pharmaceutical compositions
|
US7378108B1
(en)
|
1999-02-19 |
2008-05-27 |
Takeda Pharmaceutical Company Limited |
Percutaneous absorption preparation of compound having angiotensin II antagonistic activity
|
US6211217B1
(en)
|
1999-03-16 |
2001-04-03 |
Novartis Ag |
Method for reducing pericardial fibrosis and adhesion formation
|
WO2000076489A2
(en)
*
|
1999-06-10 |
2000-12-21 |
Warner-Lambert Company |
Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
|
US6972287B1
(en)
|
1999-06-10 |
2005-12-06 |
Pfizer Inc. |
Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
|
EP1197226B1
(en)
*
|
1999-07-21 |
2007-11-21 |
Takeda Pharmaceutical Company Limited |
Agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
|
SE9903028D0
(sv)
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
CA2382549C
(en)
*
|
1999-08-30 |
2005-03-15 |
Aventis Pharma Deutschland Gmbh |
Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
|
PL356422A1
(en)
|
2000-02-18 |
2004-06-28 |
Takeda Chemical Industries, Ltd. |
Tnf-alpha inhibitors
|
SE0002353D0
(sv)
*
|
2000-06-22 |
2000-06-22 |
Astrazeneca Ab |
New use
|
WO2002014319A2
(en)
*
|
2000-08-11 |
2002-02-21 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
PE20020617A1
(es)
|
2000-08-22 |
2002-08-05 |
Novartis Ag |
Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
|
EP1314425A4
(en)
*
|
2000-08-30 |
2004-06-02 |
Sankyo Co |
MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
|
CA2426674A1
(en)
*
|
2000-10-25 |
2002-05-02 |
Takeda Chemical Industries, Ltd. |
Agent for preventing or treating portal hypertension
|
US8168616B1
(en)
|
2000-11-17 |
2012-05-01 |
Novartis Ag |
Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
|
CA2430934C
(en)
|
2000-12-01 |
2011-06-21 |
Takeda Chemical Industries, Ltd. |
A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
|
EP1420016A4
(en)
*
|
2001-08-03 |
2006-11-15 |
Takeda Pharmaceutical |
CRYSTAL AND METHOD FOR MANUFACTURING THE SAME
|
WO2003020315A1
(fr)
*
|
2001-08-28 |
2003-03-13 |
Sankyo Company, Limited |
Compositions medicinales contenant un antagoniste du recepteur d'angiotensine ii
|
US7107198B2
(en)
*
|
2001-11-02 |
2006-09-12 |
Sun Microsystems, Inc. |
Automatic generation of reduced-size circuit models including inductive interaction
|
EP1444988A4
(en)
|
2001-11-13 |
2007-04-25 |
Takeda Pharmaceutical |
CANCER AGENT
|
DE10205335A1
(de)
*
|
2002-02-07 |
2003-08-21 |
Bdd Group Holding Ag Zug |
Deuterierte biphenylsubstituierte Benzimidazole sowie diese Verbindungen enthaltende Arzneimittel
|
JP2005531508A
(ja)
*
|
2002-03-01 |
2005-10-20 |
メルク エンド カムパニー インコーポレーテッド |
Edg受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
|
US7232828B2
(en)
|
2002-08-10 |
2007-06-19 |
Bethesda Pharmaceuticals, Inc. |
PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
|
CN1681495B
(zh)
|
2002-08-19 |
2010-05-12 |
辉瑞产品公司 |
用于治疗过度增生性疾病的组合物
|
DE10335027A1
(de)
|
2003-07-31 |
2005-02-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von Angiotensin II Rezeptor Antagonisten
|
CA2519490A1
(en)
*
|
2003-03-17 |
2004-09-30 |
Teva Pharmaceutical Industries Ltd |
Polymorphis of valsartan
|
US7504516B2
(en)
*
|
2003-03-27 |
2009-03-17 |
Hetero Drugs Limited |
Crystalline forms of candesartan cilexetil
|
SE0300988D0
(sv)
*
|
2003-04-03 |
2003-04-03 |
Astrazeneca Ab |
New use
|
WO2004094391A2
(en)
|
2003-04-21 |
2004-11-04 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of valsartan and intermediates thereof
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
GB0316546D0
(en)
*
|
2003-07-15 |
2003-08-20 |
Novartis Ag |
Process for the manufacture of organic compounds
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
ES2348300T3
(es)
*
|
2003-08-27 |
2010-12-02 |
Zentiva, K.S. |
Procedimiento para eliminar el grupo protector trifenilmetano.
|
GB0322552D0
(en)
*
|
2003-09-26 |
2003-10-29 |
Astrazeneca Uk Ltd |
Therapeutic treatment
|
TW200523257A
(en)
*
|
2003-09-26 |
2005-07-16 |
Novartis Ag |
Use of organic compounds
|
CA2542499A1
(en)
*
|
2003-10-16 |
2005-04-28 |
Teva Pharmaceutical Industries Ltd. |
Preparation of candesartan cilexetil
|
US20070292498A1
(en)
*
|
2003-11-05 |
2007-12-20 |
Warren Hall |
Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
|
WO2005051298A2
(en)
|
2003-11-19 |
2005-06-09 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
WO2005051928A1
(en)
*
|
2003-11-28 |
2005-06-09 |
Ranbaxy Laboratories Limited |
Process for production of tetrazolyl compounds
|
GB0327839D0
(en)
|
2003-12-01 |
2003-12-31 |
Novartis Ag |
Organic compounds
|
JP2005206603A
(ja)
*
|
2004-01-21 |
2005-08-04 |
Teva Pharmaceutical Industries Ltd |
カンデサルタンシレキセチルの調製
|
GB0402262D0
(en)
|
2004-02-02 |
2004-03-10 |
Novartis Ag |
Process for the manufacture of organic compounds
|
WO2005077941A2
(en)
*
|
2004-02-11 |
2005-08-25 |
Teva Pharmaceutical Industries Ltd. |
Candesartan cilexetil polymorphs
|
US7157584B2
(en)
|
2004-02-25 |
2007-01-02 |
Takeda Pharmaceutical Company Limited |
Benzimidazole derivative and use thereof
|
BRPI0508880A
(pt)
|
2004-03-17 |
2007-09-04 |
Novartis Ag |
uso de compostos orgánicos
|
CA2561700A1
(en)
*
|
2004-04-16 |
2005-12-15 |
Santarus, Inc. |
Combination of proton pump inhibitor, buffering agent, and prokinetic agent
|
CN1953973A
(zh)
*
|
2004-05-05 |
2007-04-25 |
特瓦制药工业有限公司 |
高纯度坎地沙坦酯的制备
|
JP2005330277A
(ja)
*
|
2004-05-19 |
2005-12-02 |
Teva Pharmaceutical Industries Ltd |
カンデサルタンシレキセチル多形体
|
JP2009185060A
(ja)
*
|
2004-05-19 |
2009-08-20 |
Teva Pharmaceutical Industries Ltd |
カンデサルタンシレキセチル多形体
|
US7588779B2
(en)
*
|
2004-05-28 |
2009-09-15 |
Andrx Labs, Llc |
Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
|
WO2005123720A1
(en)
*
|
2004-06-18 |
2005-12-29 |
Ranbaxy Laboratories Limited |
Fine particles of the angiotensin ii antagonist candesartan cilexetil and process for production thereof
|
US7186749B2
(en)
|
2004-08-23 |
2007-03-06 |
Wyeth |
Pyrrolo-naphthyl acids and methods for using them
|
WO2006023865A1
(en)
|
2004-08-23 |
2006-03-02 |
Wyeth |
Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
|
BRPI0514572A
(pt)
|
2004-08-23 |
2008-06-17 |
Wyeth Corp |
ácidos de tiazolo-naftila
|
PL1799199T3
(pl)
|
2004-10-08 |
2012-09-28 |
Novartis Ag |
Zastosowanie inhibitorów reniny do zapobiegania lub leczenia dysfunkcji rozkurczowej albo rozkurczowej niewydolności serca
|
NZ555325A
(en)
|
2004-10-27 |
2009-07-31 |
Daiichi Sankyo Co Ltd |
Benzene compound having 2 or more substituents
|
JPWO2006046528A1
(ja)
*
|
2004-10-29 |
2008-05-22 |
興和株式会社 |
糸球体疾患治療剤
|
EP1655298A1
(en)
*
|
2004-11-03 |
2006-05-10 |
LEK Pharmaceuticals d.d. |
Novel polymorph forms of candesartan cilexetil
|
WO2006050922A1
(en)
|
2004-11-11 |
2006-05-18 |
Lek Pharmaceuticals D.D. |
Process for the synthesis of tetrazoles
|
AP2007003979A0
(en)
*
|
2004-11-23 |
2007-06-30 |
Warner Lambert Co |
7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
|
DE102004060699A1
(de)
*
|
2004-12-16 |
2006-06-22 |
Ratiopharm Gmbh |
Verfahren zur Herstellung von Candesartan
|
PT1833801E
(pt)
*
|
2004-12-22 |
2008-08-25 |
Algry Quimica S L |
Compostos intermediários para a preparação de antagonistas do receptor da angiotensina ii
|
WO2006074218A2
(en)
*
|
2005-01-06 |
2006-07-13 |
Elan Pharma International Ltd. |
Nanoparticulate candesartan formulations
|
CN101103021A
(zh)
*
|
2005-01-14 |
2008-01-09 |
特瓦制药工业有限公司 |
粗坎地沙坦西酯的制备
|
WO2006079496A1
(en)
*
|
2005-01-26 |
2006-08-03 |
Lek Pharmaceuticals D.D. |
New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance
|
EP1863801B1
(en)
*
|
2005-03-30 |
2010-09-29 |
Takeda Pharmaceutical Company Limited |
Benzimidazole derivative and use thereof
|
TW200719896A
(en)
*
|
2005-04-18 |
2007-06-01 |
Astrazeneca Ab |
Combination product
|
CN100400536C
(zh)
*
|
2005-04-30 |
2008-07-09 |
重庆圣华曦药业有限公司 |
坎地沙坦酯c-型晶体的制备方法
|
KR100978592B1
(ko)
*
|
2005-05-10 |
2010-08-27 |
테바 파마슈티컬 인더스트리즈 리미티드 |
안정한 미세 분말 칸데사탄 실렉세틸 및 이것의 제조 방법
|
EP1896455A2
(en)
*
|
2005-06-06 |
2008-03-12 |
Medichem, S.A. |
Process for the preparation of tetrazolyl compounds
|
ES2264641B1
(es)
*
|
2005-06-17 |
2008-03-01 |
Quimica Sintetica, S.A. |
Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
|
EP1904483A1
(en)
|
2005-07-13 |
2008-04-02 |
F. Hoffmann-Roche AG |
Benzimidazole derivatives as 5-ht6,5-ht24
|
SI22127A
(sl)
*
|
2005-10-07 |
2007-04-30 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Postopek za pripravo kandesartan cileksetila
|
CZ299265B6
(cs)
*
|
2005-10-20 |
2008-05-28 |
Zentiva, A. S. |
Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
CN100344625C
(zh)
*
|
2005-12-22 |
2007-10-24 |
浙江天宇药业有限公司 |
一种制备坎地沙坦的方法
|
US7943780B2
(en)
*
|
2006-02-15 |
2011-05-17 |
Matrix Laboratories Ltd. |
Process for the preparation of candesartan cilexetil
|
CN101024643A
(zh)
|
2006-02-20 |
2007-08-29 |
上海艾力斯医药科技有限公司 |
咪唑-5-羧酸类衍生物、制备方法及其应用
|
WO2008035360A2
(en)
*
|
2006-06-13 |
2008-03-27 |
Alembic Limited |
Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil
|
EP2066649A1
(en)
*
|
2006-07-28 |
2009-06-10 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Process for the preparation of amorphous and crystalline forms of candesartan cilexetil using column chromatography
|
CA2660427A1
(en)
|
2006-08-10 |
2008-02-14 |
Takeda Pharmaceutical Company Limited |
Pharmaceutical composition
|
CA2665226C
(en)
|
2006-10-05 |
2014-05-13 |
Santarus, Inc. |
Novel formulations of proton pump inhibitors and methods of using these formulations
|
EP1908469A1
(en)
|
2006-10-06 |
2008-04-09 |
Boehringer Ingelheim Vetmedica Gmbh |
Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
|
WO2008044244A2
(en)
*
|
2006-10-10 |
2008-04-17 |
Matrix Laboratories Ltd |
One pot process for the preparation of candesartan
|
EP2486910A3
(en)
|
2006-10-27 |
2012-08-22 |
The Curators Of The University Of Missouri |
Multi-chambered apparatus comprising a dispenser head
|
ES2315141B1
(es)
*
|
2006-11-23 |
2009-12-22 |
Quimica Sintetica, S.A |
Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
|
JP5498168B2
(ja)
|
2006-12-01 |
2014-05-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
アテローム性動脈硬化および循環器疾患の治療のためのcetp阻害剤としてのn−((3−ベンジル)−2,2−(ビス−フェニル)−プロパン−1−アミン誘導体
|
KR101112515B1
(ko)
*
|
2006-12-06 |
2012-02-24 |
상하이 알리스트 파마슈티컬즈 인코포레이티드 |
이미다졸-5- 카복실산 유도체의 염 및 그 제조방법 및 상기 염으로 구성되는 약학 조성물
|
CN101214242A
(zh)
|
2007-01-05 |
2008-07-09 |
上海艾力斯医药科技有限公司 |
新的药用组合物
|
EP1952806A1
(en)
|
2007-02-01 |
2008-08-06 |
Helm AG |
Process for the preparation of adsorbates of candesartan
|
TW200838501A
(en)
|
2007-02-02 |
2008-10-01 |
Theravance Inc |
Dual-acting antihypertensive agents
|
KR101126383B1
(ko)
|
2007-02-07 |
2012-04-12 |
교와 핫꼬 기린 가부시키가이샤 |
3환계 화합물
|
US20080194307A1
(en)
*
|
2007-02-13 |
2008-08-14 |
Jeff Sanger |
Sports-based game of chance
|
EP2117540A1
(en)
|
2007-03-01 |
2009-11-18 |
Probiodrug AG |
New use of glutaminyl cyclase inhibitors
|
US20090048316A1
(en)
*
|
2007-03-08 |
2009-02-19 |
Minutza Leibovici |
Pharmaceutical composition comprising candesartan cilexetil
|
NZ579851A
(en)
*
|
2007-03-28 |
2012-02-24 |
Takeda Pharmaceutical |
Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent
|
JP5667440B2
(ja)
|
2007-04-18 |
2015-02-12 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
|
SI22488A
(sl)
*
|
2007-04-24 |
2008-10-31 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Kristalni 1-(cikloheksiloksikarboniloksi)etil 1-((2'-cianobifenil-4-il)metil) - 2-etoksi-1h-benz(d)imidazol -7-karboksilat in proces za njegovo pripravo
|
TWI448284B
(zh)
|
2007-04-24 |
2014-08-11 |
Theravance Inc |
雙效抗高血壓劑
|
RU2009141539A
(ru)
|
2007-04-25 |
2011-05-27 |
Тева Фармасьютикал Индастриес Лтд. (Il) |
Комплекс фармацевтического наполнителя
|
MX354786B
(es)
|
2007-06-04 |
2018-03-21 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
TWI406850B
(zh)
*
|
2007-06-05 |
2013-09-01 |
Theravance Inc |
雙效苯并咪唑抗高血壓劑
|
EP2170868A1
(en)
*
|
2007-07-11 |
2010-04-07 |
Alembic Limited |
An improved process for the preparation of candesartan cilexetil
|
EP2200975A1
(en)
|
2007-09-07 |
2010-06-30 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
US8212052B2
(en)
|
2007-12-11 |
2012-07-03 |
Theravance, Inc. |
Dual-acting benzoimidazole antihypertensive agents
|
EP2252274A4
(en)
|
2008-02-20 |
2011-05-11 |
Univ Missouri |
COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME
|
US7989484B2
(en)
|
2008-04-29 |
2011-08-02 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
CA2726917C
(en)
|
2008-06-04 |
2018-06-26 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
WO2009157001A2
(en)
*
|
2008-06-24 |
2009-12-30 |
Hetero Research Foundation |
Process for preparation of candesartan cilexetil
|
WO2010009319A2
(en)
|
2008-07-16 |
2010-01-21 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
EP2334651A2
(en)
|
2008-07-24 |
2011-06-22 |
Theravance, Inc. |
Dual-acting antihypertensive agents
|
CN101648918B
(zh)
*
|
2008-08-15 |
2013-01-09 |
联化科技股份有限公司 |
坎地沙坦酯的中间体化合物及其合成方法
|
PT2165702E
(pt)
|
2008-09-17 |
2012-02-07 |
Helm Ag |
Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida
|
EA201170549A1
(ru)
*
|
2008-10-10 |
2012-01-30 |
Янссен Фармацевтика Нв |
Комбинированная терапия с использованием блокаторов рецепторов ангиотензина и антагонистов рецепторов вазопрессина
|
KR100995755B1
(ko)
|
2008-10-31 |
2010-11-19 |
일동제약주식회사 |
트리틸 칸데사르탄 실렉세틸의 개선된 제조방법
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
WO2010075347A2
(en)
|
2008-12-23 |
2010-07-01 |
Takeda Pharmaceutical Company Limited |
Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
US7956054B2
(en)
|
2009-07-07 |
2011-06-07 |
Theravance, Inc. |
Dual-acting pyrazole antihypertensive agents
|
WO2011011232A1
(en)
|
2009-07-22 |
2011-01-27 |
Theravance, Inc. |
Dual-acting oxazole antihypertensive agents
|
SG178953A1
(en)
|
2009-09-11 |
2012-04-27 |
Probiodrug Ag |
Heterocylcic derivatives as inhibitors of glutaminyl cyclase
|
WO2011080684A1
(en)
|
2009-12-31 |
2011-07-07 |
Ranbaxy Laboratories Limited |
Process for the preparation of candesartan cilexetil
|
WO2011090929A1
(en)
|
2010-01-19 |
2011-07-28 |
Theravance, Inc. |
Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
|
WO2011092666A1
(en)
|
2010-01-29 |
2011-08-04 |
Ranbaxy Laboratories Limited |
An improved process for the preparation of candesartan cilexetil, polymorphic forms of n-trityl candesartan and their uses thereof
|
US9181233B2
(en)
|
2010-03-03 |
2015-11-10 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
AU2011226074B2
(en)
|
2010-03-10 |
2015-01-22 |
Vivoryon Therapeutics N.V. |
Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
|
US8541596B2
(en)
|
2010-04-21 |
2013-09-24 |
Probiodrug Ag |
Inhibitors
|
CN101880241B
(zh)
*
|
2010-07-14 |
2013-04-17 |
浙江美诺华药物化学有限公司 |
一锅法制备2-(取代苯基)甲氨基-3-硝基苯甲酸甲酯的方法
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
KR101251741B1
(ko)
*
|
2010-12-16 |
2013-04-05 |
동화약품주식회사 |
칸데사르탄실렉세틸의 개선된 제조방법
|
ES2570167T3
(es)
|
2011-03-16 |
2016-05-17 |
Probiodrug Ag |
Derivados de benzimidazol como inhibidores de glutaminil ciclasa
|
CN102198129B
(zh)
*
|
2011-03-22 |
2016-03-30 |
浙江华海药业股份有限公司 |
含有坎地沙坦酯和氢氯噻嗪的口服片剂
|
CN102206186A
(zh)
*
|
2011-04-18 |
2011-10-05 |
张家港市信谊化工有限公司 |
坎地沙坦环合物的制备方法
|
CN103906508A
(zh)
|
2011-08-26 |
2014-07-02 |
沃克哈特有限公司 |
治疗心血管疾病的方法
|
WO2013041944A1
(en)
|
2011-09-19 |
2013-03-28 |
Ranbaxy Laboratories Limited |
Process for the preparation of micronized candesartan cilexetil
|
JP5850697B2
(ja)
*
|
2011-10-18 |
2016-02-03 |
株式会社トクヤマ |
カンデサルタンシレキセチルの製造方法
|
WO2013090196A1
(en)
|
2011-12-15 |
2013-06-20 |
Takeda Pharmaceuticals U.S.A., Inc. |
Combinations of azilsartan and chlorthalidone for treating hypertension black patients
|
CN102391254B
(zh)
*
|
2011-12-16 |
2013-03-13 |
珠海润都制药股份有限公司 |
一种坎地沙坦的制备方法
|
CN103304543A
(zh)
*
|
2012-03-12 |
2013-09-18 |
邓俐丽 |
一种坎地沙坦酯的制备方法
|
CN102633816A
(zh)
*
|
2012-03-30 |
2012-08-15 |
李莎 |
头孢西丁酯化前体药物化合物及口服制剂
|
AU2013255050B2
(en)
|
2012-05-01 |
2016-07-28 |
Translatum Medicus Inc. |
Methods for treating and diagnosing blinding eye diseases
|
BR112014027618A2
(pt)
|
2012-05-07 |
2017-06-27 |
Bayer Pharma AG |
processo para a fabricação de uma forma de dosagem farmacêutica compreendendo nifedipina e candesartan cilexetil
|
US20140134187A1
(en)
|
2012-06-25 |
2014-05-15 |
The Johns Hopkins University |
Therapeutic and diagnostic methods for autism spectrum disorders and other conditions
|
US9486503B2
(en)
|
2012-10-04 |
2016-11-08 |
Shionogi & Co., Ltd. |
Medicinal agent for suppressing malignant tumor metastasis
|
CN102952040A
(zh)
*
|
2012-11-20 |
2013-03-06 |
峨眉山天梁星制药有限公司 |
一种坎地沙坦酯中间体的硝基还原为氨基的方法
|
PL236001B1
(pl)
|
2012-12-21 |
2020-11-30 |
Adamed Spolka Z Ograniczona Odpowiedzialnoscia |
Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
US9339542B2
(en)
*
|
2013-04-16 |
2016-05-17 |
John L Couvaras |
Hypertension reducing composition
|
EP2986599A1
(en)
|
2013-04-17 |
2016-02-24 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
ES2847904T3
(es)
|
2013-07-23 |
2021-08-04 |
Daiichi Sankyo Co Ltd |
Medicamento para la prevención o el tratamiento de la hipertensión
|
CN104098550A
(zh)
*
|
2014-07-17 |
2014-10-15 |
浙江华海药业股份有限公司 |
一种精制三苯甲基坎地沙坦的方法
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
WO2016192099A1
(zh)
*
|
2015-06-05 |
2016-12-08 |
浙江华海药业股份有限公司 |
一种制备三苯甲基坎地沙坦的方法
|
CZ2015687A3
(cs)
|
2015-10-02 |
2017-04-12 |
Zentiva, K.S. |
Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu
|
EP3219309A1
(en)
|
2016-03-17 |
2017-09-20 |
K.H.S. Pharma Holding GmbH |
Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
|
CN108778334A
(zh)
|
2016-03-24 |
2018-11-09 |
第三共株式会社 |
用于治疗肾脏疾病的药物
|
CN106432201B
(zh)
*
|
2016-09-14 |
2019-04-23 |
威海迪素制药有限公司 |
一种坎地沙坦酯结晶的制备方法
|
CA3067918A1
(en)
|
2017-07-07 |
2019-01-10 |
Boehringer Ingelheim Vetmedica Gmbh |
Angiotensin ii receptor antagonish for the prevention or treatment of hypertension in cats
|
ES2812698T3
(es)
|
2017-09-29 |
2021-03-18 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
US11660266B2
(en)
|
2018-04-11 |
2023-05-30 |
Ohio State Innovation Foundation |
Methods and compositions for sustained release microparticles for ocular drug delivery
|
US20220089526A1
(en)
|
2019-01-02 |
2022-03-24 |
Linhai Huanan Chemical Co., Ltd. |
Synthesis Method for Candesartan Cilexetil Intermediate
|
BR112021013807A2
(pt)
|
2019-01-18 |
2021-11-30 |
Astrazeneca Ab |
Inibidores de pcsk9 e seus métodos de uso
|
CN110514758A
(zh)
*
|
2019-08-21 |
2019-11-29 |
天地恒一制药股份有限公司 |
一种坎地沙坦酯有关物质的检测方法
|
WO2022033202A1
(zh)
*
|
2020-08-13 |
2022-02-17 |
南京海融医药科技股份有限公司 |
布洛芬酯类前药、药物组合物以及制备方法和应用
|
US11655220B2
(en)
|
2020-10-22 |
2023-05-23 |
Hetero Labs Limited |
Process for the preparation of angiotensin II receptor blockers
|
EP4052695A1
(en)
|
2021-03-05 |
2022-09-07 |
Midas Pharma GmbH |
Stable oral fixed-dose immediate release pharmaceutical compositions comprising amlodipine, atorvastatin and candesartan cilexetil
|
EP4370101A1
(en)
|
2021-07-15 |
2024-05-22 |
Adamed Pharma S.A. |
A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
|
CN114149414B
(zh)
*
|
2021-12-23 |
2023-08-04 |
浙江永宁药业股份有限公司 |
一种利用微反应器连续流制备坎地沙坦的方法
|
WO2024075017A1
(en)
|
2022-10-04 |
2024-04-11 |
Zabirnyk Arsenii |
Inhibition of aortic valve calcification
|
EP4374855A1
(en)
|
2022-11-22 |
2024-05-29 |
KRKA, D.D., Novo Mesto |
Pharmaceutical dosage form of candesartan and indapamide
|